Among BRD4 targets, we also identified CEACAM1, which was reported to inhibit NK-mediated cytolysis of tumor cells47,48 and KLRG1, a negative regulator of CD8+ lymphocytes and NK cells49. Here, CEACAM1 is linked to neoplasm.